Skip to main content

Table 4 Differentially expressed miRNAs (n=21) with an inconsistent direction between two studies

From: Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance

 miRNA name Direction of expression Studies with same direction (reference) No. of tissue samples tested Mean fold-change Mean rank
hsa-miR-103 AE, AP, AS, NB 167 2.72 87.00
  SZ 20 1.73 5.00
hsa-let-7d EJ, AP 32 6.82 11.50
  SA, AE 37 7.04 22.50
hsa-miR-26a AP 17 5.16 12.00
  AE, AS, SA 131 4.38 30.67
hsa-miR-146a AE, AS 102 2.08 12.00
  SA 29 3.03 9.00
hsa-miR-708 AS, NA 254 3.15 43.50
  NB 48 9.26 7.00
hsa-miR-345 AS 94 1.45 85.00
  EJ, NB 63 12.59 2.50
hsa-miR-376a EJ 15 7.79 17.00
  AE, AS 102 1.43 28.00
hsa-miR-494 NA 160 4.23 41.00
  NB, AE 56 3.86 14.50
hsa-miR-423-5p SA 29 9.03 4.00
  YN, NB 113 2.77 30.00
hsa-miR-365 SZ 20 1.75 2.00
  AE, AS 102 1.80 17.00
hsa-miR-130a NB 48 2.00 28.00
  AE, AS 102 1.62 29.50
hsa-miR-132 AS 94 2.59 18.00
  SZ 20 3.05 1.00
hsa-miR-324-3p AS 94 1.95 39.00
  NB 48 2.16 50.00
hsa-miR-501-5p AS 94 1.59 64.00
  NB 48 2.02 52.00
hsa-miR-874 AS 94 1.49 80.00
  NB 48 2.20 47.00
hsa-miR-518d-3p AS 94 1.30 103.00
  NA 160 15.35 9.00
hsa-miR-28-3p AS 94 1.28 104.00
  NB 48 4.49 23.00
hsa-miR-648 NA 160 8.63 16.00
  NB 48 9.07 8.00
hsa-miR-575 NA 160 7.52 22.00
  NB 48 4.38 24.00
hsa-miR-877 NA 160 4.03 43.00
  NB 48 3.48 28.00
hsa-let-7g NB 48 2.44 21.00
  AE 8 1.06 45.00